About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2011 (2011), Article ID 394730, 5 pages
Research Article

Rabbit Model of Retinoblastoma

L.F. Montgomery Ophthalmic Pathology Laboratory, Department of Ophthalmology, Emory Eye Center, Emory University School of Medicine, 1365-B Clifton Road NE, Atlanta, GA 30322, USA

Received 14 September 2010; Accepted 9 December 2010

Academic Editor: Monica Fedele

Copyright © 2011 Shin Jeong Kang and Hans E. Grossniklaus. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. L. Wong, J. D. Boice Jr., D. H. Abramson et al., “Cancer incidence after retinoblastoma: radiation dose and sarcoma risk,” Journal of the American Medical Association, vol. 278, no. 15, pp. 1262–1267, 1997. View at Scopus
  2. D. H. Abramson and C. M. Frank, “Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk,” Ophthalmology, vol. 105, no. 4, pp. 573–580, 1998. View at Publisher · View at Google Scholar
  3. G. J. Draper, B. M. Sander, and J. E. Kingston, “Second primary neoplasms in patients with retinoblastoma,” British Journal of Cancer, vol. 53, no. 5, pp. 661–671, 1986. View at Scopus
  4. L. B. Travis, E. J. Holowaty, K. Bergfeldt et al., “Risk of leukemia after platinum-based chemotherapy for ovarian cancer,” The New England Journal of Medicine, vol. 340, no. 5, pp. 351–357, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. M. A. Smith, L. Rubinstein, J. R. Anderson et al., “Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins,” Journal of Clinical Oncology, vol. 17, no. 2, pp. 569–577, 1999. View at Scopus
  6. J. H. Gerlach, N. Kartner, D. R. Bell, and V. Ling, “Multidrug resistance,” Cancer Surveys, vol. 5, no. 1, pp. 25–46, 1986. View at Scopus
  7. D. H. Abramson, C. M. Frank, and I. J. Dunkel, “A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma,” Ophthalmology, vol. 106, no. 10, pp. 1947–1950, 1999. View at Scopus
  8. I. Schmack, G. B. Hubbard, S. J. Kang, T. M. Aaberg, and H. E. Grossniklaus, “Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma,” American Journal of Ophthalmology, vol. 142, no. 2, pp. 310–e2, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. J. J. Windle, D. M. Albert, J. M. O'Brien et al., “Retinoblastoma in transgenic mice,” Nature, vol. 343, no. 6259, pp. 665–669, 1990. View at Publisher · View at Google Scholar · View at Scopus
  10. P. L. Blanco, J. C. A. Marshall, E. Antecka et al., “Characterization of ocular and metastatic uveal melanoma in an animal model,” Investigative Ophthalmology and Visual Science, vol. 46, no. 12, pp. 4376–4382, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Chevez-Barrios, M. Y. Hurwitz, K. Louie et al., “Metastatic and nonmetastatic models of retinoblastoma,” American Journal of Pathology, vol. 157, no. 4, pp. 1405–1412, 2000. View at Scopus
  12. M. W. Wilson, C. Rodriguez-Galindo, B. G. Haik, D. M. Moshfeghi, T. E. Merchant, and C. B. Pratt, “Multiagent chemotherapy as neoadjuvant treatment for multifocal intraocular retinoblastoma,” Ophthalmology, vol. 108, no. 11, pp. 2106–2114, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. D. L. Friedman, B. Himelstein, C. L. Shields et al., “Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma,” Journal of Clinical Oncology, vol. 18, no. 1, pp. 12–17, 2000. View at Scopus
  14. C. Rodriguez-Galindo, M. W. Wilson, B. G. Haik et al., “Treatment of intraocular retinoblastoma with vincristine and carboplatin,” Journal of Clinical Oncology, vol. 21, no. 10, pp. 2019–2025, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. L. White, C. Reed, and V. Tobias, “Comparison of cyclophosphamide and diaziquone in a retinoblastoma xenograft model,” Ophthalmic Paediatrics and Genetics, vol. 10, no. 2, pp. 99–105, 1989. View at Scopus
  16. D. Chen, S. Pajovic, A. Duckett, V. D. Brown, J. A. Squire, and B. L. Gallie, “Genomic amplification in retinoblastoma narrowed to 0.6 megabase on chromosome 6p containing a kinesin-like gene, RBKIN,” Cancer Research, vol. 62, no. 4, pp. 967–971, 2002. View at Scopus
  17. J. A. Mietz, T. Unger, J. M. Huibregtse, and P. M. Howley, “The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein,” The EMBO Journal, vol. 11, no. 13, pp. 5013–5020, 1992. View at Scopus
  18. D. Chen, I. Livne-bar, J. L. Vanderluit, R. S. Slack, M. Agochiya, and R. Bremner, “Cell-specific effects of RB or RB/p107 loss on retinal development implicate an intrinsically death-resistant cell-of-origin in retinoblastoma,” Cancer Cell, vol. 5, no. 6, pp. 539–551, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Zhang, B. Schweers, and M. A. Dyer, “The first knockout mouse model of retinoblastoma,” Cell Cycle, vol. 3, no. 7, pp. 952–959, 2004. View at Scopus
  20. D. MacPherson, J. Sage, T. Kim, D. Ho, M. E. McLaughlin, and T. Jacks, “Cell type-specific effects of Rb deletion in the murine retina,” Genes and Development, vol. 18, no. 14, pp. 1681–1694, 2004. View at Publisher · View at Google Scholar · View at Scopus